ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2062

Omentin-1: Potential Biomarker of Cardiovascular Risk in Axial Spondyloarthritis? a Serological and Genetic Study

Fernanda Genre1, Javier Rueda-Gotor1, Sara Remuzgo-Martínez1, Verónica Pulito-Cueto1, Alfonso Corrales1, Verónica Mijares1, Leticia Lera-Gómez1, Virginia Portilla1, Rosa Expósito2, Cristina Mata2, Iván Ferraz-Amaro3, M. Vanesa Hernandez-Hernandez4, Santos Castañeda5, Esther Vicente5, Cristina Fernández-Carballido6, María Paz Martínez-Vidal7, David Castro-Corredor8, Joaquín Anino-Fernández8, Ricardo Blanco1, Oreste Gualillo9, Javier Martin10, Javier Llorca11, Raquel Lopez-Mejías1 and Miguel Angel González-Gay1,12, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Rheumatology Division, Hospital Comarcal de Laredo, Laredo, Spain, 3Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 4Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, 5Rheumatology Division, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 6Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, 7Rheumatology Division, Hospital General Universitario de Alicante, Alicante, Spain, 8Rheumatology Division, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 9SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 10Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain., Granada, Spain, 11Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 12School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: axial spondyloarthritis, biomarkers and cardiovascular disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular (CV) disease (mainly due to accelerated atherosclerosis) is one of the main causes of mortality in axial spondyloarthritis (axSpA). The higher incidence of CV risk factors and systemic chronic inflammation increase CV risk in axSpA.1 This is further enhanced by dysregulated production of adipokines, molecules with key metabolic and immunomodulatory functions. In this regard, low levels of circulating omentin-1, an anti-inflammatory adipokine, have been associated with metabolic dysfunction and CV disease in general population and other conditions different from axSpA.2,3 Therefore, the aim of this study was to evaluate the potential role of omentin-1 as a prognostic marker of CV disease in axSpA by assessing its association with subclinical atherosclerosis and CV risk factors in a large cohort of patients, both at the serological and genetic level.

Methods: 299 patients that fulfilled the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA4 and 84 controls were recruited for this study. Clinical data was retrieved from medical records. Serum omentin-1 levels were assessed by ELISA. Carotid US was performed to evaluate the presence of subclinical atherosclerosis. One polymorphism of the gene coding Omentin-1 (ITLN-1 rs12409609), previously associated with coronary artery disease, was genotyped by TaqMan probes. Statistical analysis of the data was performed using STATA® v. 11.1, adjusting the results by potential confounding factors.

Results: Serum omentin-1 levels were significantly lower in axSpA when compared to controls (p=0.0001). Additionally, serum omentin-1 negatively correlated with body mass index (p=0.002) and atherogenic index (p=0.009) in axSpA. Interestingly, axSpA patients with inflammatory bowel disease exhibited lower omentin-1 serum levels when compared to patients not displaying this extra-articular manifestation (p=0.005). Neither serum omentin-1 levels nor ITLN-1 rs12409609 showed statistically significant association with markers of subclinical atherosclerosis. Likewise, ITLN-1 rs12409609 did not disclose a statistically significant association with omentin-1 serum levels.

Conclusion: Serum omentin-1 is linked to obesity and adverse lipid profiles in axSpA. Additionally, serum levels of this molecule are associated with the presence of inflammatory bowel disease in axSpA. These data support a role of omentin-1 as a CV risk biomarker in axSpA.

[1] Joint Bone Spine. 2014; 81(1):57-63. [2] Cardiovasc Hematol Disord Drug Targets. 2013; 13(1):59-72. [3] Curr Issues Pharm Med Sci. 2015; 28(3):176-80. [4] Ann Rheum Dis. 2009; 68(6):777-83.

This work was supported by funds of a NEXT-VAL grant (NVAL17/10)(IDIVAL). FG is a recipient of a Sara Borrell fellowship (Instituto de Salud Carlos III –ISCIII-, co-funded by European Social Fund –ESF-,“Investing in your future”,CD15/00095). SR-M is supported by funds of RETICS Program (RD16/0012/0009,ISCIII,co-funded by European Regional Development Fund,ERDF). RL-M is a recipient of a Miguel Servet type I fellowship (ISCIII, co-funded by ESF, CP16/00033). VM is supported by funds of a Miguel Servet type I programme (CP16/00033)(ISCIII, co-funded by ERDF).


Disclosure: F. Genre, None; J. Rueda-Gotor, None; S. Remuzgo-Martínez, None; V. Pulito-Cueto, None; A. Corrales, None; V. Mijares, None; L. Lera-Gómez, None; V. Portilla, None; R. Expósito, None; C. Mata, None; I. Ferraz-Amaro, None; M. V. Hernandez-Hernandez, None; S. Castañeda, None; E. Vicente, None; C. Fernández-Carballido, None; M. P. Martínez-Vidal, None; D. Castro-Corredor, None; J. Anino-Fernández, None; R. Blanco, None; O. Gualillo, None; J. Martin, None; J. Llorca, None; R. Lopez-Mejías, None; M. A. González-Gay, None.

To cite this abstract in AMA style:

Genre F, Rueda-Gotor J, Remuzgo-Martínez S, Pulito-Cueto V, Corrales A, Mijares V, Lera-Gómez L, Portilla V, Expósito R, Mata C, Ferraz-Amaro I, Hernandez-Hernandez MV, Castañeda S, Vicente E, Fernández-Carballido C, Martínez-Vidal MP, Castro-Corredor D, Anino-Fernández J, Blanco R, Gualillo O, Martin J, Llorca J, Lopez-Mejías R, González-Gay MA. Omentin-1: Potential Biomarker of Cardiovascular Risk in Axial Spondyloarthritis? a Serological and Genetic Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/omentin-1-potential-biomarker-of-cardiovascular-risk-in-axial-spondyloarthritis-a-serological-and-genetic-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/omentin-1-potential-biomarker-of-cardiovascular-risk-in-axial-spondyloarthritis-a-serological-and-genetic-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology